SDGR vs RLAY
SDGR and RLAY side by side — valuation & fundamentals (public data).
Key statistics
| Metric | SDGRSchrodinger, Inc. | RLAYRelay Therapeutics, Inc. |
|---|---|---|
| Market cap | — | $3.83B |
| P/S | — | 249.3x |
| Revenue | $259.04M(TTM) | — |
| Revenue growth (YoY) | 23.3% | 53.4% |
| Net income | -$54.34M(TTM) | — |
| Earnings growth (YoY) | 44.8% | 18.1% |
| EPS, diluted | $-0.73(TTM) | — |
| EBIT margin | -65.2% | -1971.6% |
| ROE | -31.4% | -31.1% |
| 1y total return | +33.4% | +154.9% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: SDGR vs RLAY
| Metric | SDGR | RLAY |
|---|---|---|
| End value | $3.4K | $5.0K |
| Total return | -66.1% | -50.2% |
| CAGR | -15.8% | -10.5% |
| Volatility | 65.8% | 76.3% |
| Sharpe | 0.00 | 0.17 |
| Sortino | 0.00 | 0.27 |
| Max drawdown | -90.2% | -96.8% |
Based on 1585 common trading days, 2020-07-16 → 2026-11-04 · risk-free 4.21% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)